TPBG
IDXX icon

Turning Point Benefit Group’s Idexx Laboratories IDXX Stock Holding History

Turning Point Benefit Group’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2
Closed -$1.35K – 426
2025
Q4 		$1.35K Hold
2
– – ﹤0.01% 513
2025
Q3 		$1.24K Buy
+2
New +$1.21K ﹤0.01% 369

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Fundsmith LLP
Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Turning Point Benefit Group's IDXX Position: Q1 2026 in Review

Turning Point Benefit Group sold out of Idexx Laboratories (IDXX) in Q1 2026, closing a stake of 2 shares — an estimated $1.35K sold.

Turning Point Benefit Group first reported a position in IDXX in Q3 2025 and held it in 2 quarters. The position peaked at $1.35K in Q4 2025. 1,316 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • Turning Point Benefit Group reported no remaining Idexx Laboratories position as of Q1 2026 after selling out during the quarter.
  • Turning Point Benefit Group sold 2 Idexx Laboratories shares in Q1 2026, an estimated $1.35K.
  • Turning Point Benefit Group first reported a position in Idexx Laboratories in Q3 2025 and held it in 2 quarters.
  • Turning Point Benefit Group's Idexx Laboratories position peaked at $1.35K in Q4 2025.
  • 1,316 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Turning Point Benefit Group's 13F filing for Q1 2026, filed 12 May 2026.